Читать книгу Transfusion Medicine - Jeffrey McCullough - Страница 170

The official US Food and Drug Administration name of this component is platelets, pheresis. In daily practice, this component is usually called single‐donor platelets or plateletpheresis concentrates, a suspension of platelets in plasma or additive solution prepared by cytapheresis.

The use of apheresis, particularly for platelet production, is increasing substantially in many countries [44]. In 1982, about 80,000 plateletpheresis procedures were performed [45] in the United States, and by 2013, this had increased to 2,000,000 [46]. This accounted for about 90% of all platelets produced [46].

Platelets obtained by plateletpheresis are processed, tested, and labeled in a similar manner to whole blood (see Chapters 5 and 7). This includes ABO and Rh typing and testing for all required transfusion‐transmitted diseases. The number of platelets contained in each concentrate is determined, although this information may not necessarily be recorded on the label. Each platelet concentrate has a volume of approximately 200 mL and contains very few red cells (<0.5 mL), and so red cell crossmatching is not necessary. Quality‐control tests must show that at least 90% of the apheresis platelet concentrates produced by each facility contain 3 × 10¹¹ platelets or more [47]. The white blood cell (WBC) content varies depending on the instrument and technique used for collection, but presently all plateletpheresis procedures produce leukodepleted platelets (<1 × 10⁶ WBCs).